Skip to main content
search
retrospective-analysis-of-clinical-outcomes-of-stereotactic-body-radiation-therapy-for-localized-prostate-cancer-at-an-asian-cancer-specialist-centre

Abstract

Introduction

The current treatment options for localized prostate cancer are radical prostatectomy and external beam radiotherapy (EBRT) with stereotactic body radiation therapy (SBRT) gaining interest as a treatment option compared to standard fractionation radiation therapy. This present study is a retrospective study evaluating the correlations between the biochemical efficacy, and treatment toxicity in SBRT for localized prostate cancer.

Methods

All organ-confined prostate cancer patients treated with SBRT from 2010 to 2018, at Beacon Hospital, Malaysia were included in this study. Patient demographics, dosimetric parameters, and disease information were retrospectively collected. The primary endpoint was biochemical recurrence-free survival assessed using the Phoenix definition (Nadir + 2 ng/mL). Toxicity outcomes were scored using the Radiation Therapy Oncology Group scale.

Results

Fourty-nine patients who met the inclusion criteria (5 low-, 13 intermediate- and 31 high-risk according to the D’amico Risk Classification) received SBRT. The most common dose regime was 34-35Gy in 5 fractions (n=18). Other dose regimes were 24Gy in 3 fractions and 25-33Gy in 5 fractions. Median follow-up was 45.4 months. The median pre-treatment prostate-specific antigen (PSA) was 11.22 ng/mL, which decreased to a median PSA of 0.1 ng/mL by 2 years post-treatment. Out of the 49 cases, only 1 case of biochemical recurrence occurred, yielding a 3- and 5-year overall survival of 100%, and a 3- and 5- year biochemical recurrence-free rate of 100% and 95.2%. Acute grade III urinary toxicities occurred in 1 (2%); whereas acute grade I urinary and rectal toxicities were seen in 22 (44.9%) and 7 (14.3%) patients respectively. Grade I and grade III late rectal toxicities occurred in 3 and 1 patients respectively, while 3 and 1 patient reported late grade I and III urethral stricture respectively.

Conclusion

SBRT for clinically-localized and locally advanced prostate cancer provided promising outcomes with low toxicity and good biochemical control.

Download the research article to know more ;

Download Here

Featured Doctor :

dr-jasmin-loh-pei-yuin-radiationr-oncologist-beacon-hospital-malaysia

Dr Jasmin Loh Pei Yuin

Consultant Radiation Oncologist

VIEW

dr-tho-lye-mun-clinical-oncologist-beacon-hospital-malaysia

Dr Tho Lye Mun

Consultant Clinical Oncologist

VIEW

Dr-Arkonam-Balasubramaniam-Manivannan-Clinical-Oncologist-Beacon-Hospital-Malaysia

Dr Arkonam Balasubramaniam Manivannan

Consultant Clinical Oncologist

VIEW

Dato-Dr-Mohamed-Ibrahim-Bin-Dato-Hj-Abdul-Wahid-Clinical-Oncologist-Beacon-Hospital-Malaysia

Dato’ Dr Mohamed Ibrahim Bin Dato’ Hj. Abdul Wahid

Consultant Clinical Oncologist

VIEW
Close Menu